Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10537885 | 0.85 | KEAP1 (0.51) | ALDH1A1 | |
| SCHEMBL690247 | 0.84 | ALDH1A1 (0.53) | ALDH1A1 | |
| SCHEMBL179788 | 0.84 | CA2 (0.43) | MLYCDCA2CAMK2AALDH1A1ESR1 | |
| SCHEMBL6909286 | 0.83 | CA2 (0.42) | CA2ALDH1A1ESR1ESR2 | |
| SCHEMBL10538089 | 0.83 | NPSR1 (0.46) | MLYCDALDH1A1 | |
| SCHEMBL9800457 | 0.83 | MLYCD (0.40) | MLYCDALDH1A1 | |
| SCHEMBL14248561 | 0.83 | ACHE (0.44) | MLYCDALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL10539922 | 0.82 | ALDH1A1 (0.52) | ALDH1A1 | |
| SCHEMBL10536986 | 0.82 | ALDH1A1 (0.52) | ALDH1A1 | |
| SCHEMBL6470863 | 0.81 | ESR1 (0.41) | MLYCDALDH1A1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180203018-A1 | METABOLIC BIOMARKERS OF CROHN'S DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-19 | — | — | US | claimed |
| US-20050171194-A1 | Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions | YU RUEY J (US) | 2005-08-04 | — | — | US | claimed |
| WO-2005055947-A2 | ENLARGEMENT OF MUCOCUTANEOUS OR CUTANEOUS ORGANS AND SITES WITH TOPICAL COMPOSITIONS | YU RUEY J (US) | 2005-06-23 | — | — | WO | claimed |
| US-6824786-B2 | TOPICAL APPLYING COSMETIC | YU RUEY J (US) | 2004-11-30 | — | — | US | claimed |
| EP-1455734-A1 | COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES | Yu, Ruey J., Dr. (US) | 2004-09-15 | — | — | EP | claimed |
| US-20030108496-A1 | Compositions comprising phenyl-glycine derivatives | YU RUEY J (US) | 2003-06-12 | — | — | US | claimed |
| WO-2003045338-A1 | COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES | YU RUEY J (US) | 2003-06-05 | — | — | WO | claimed |
| US-20180203018-A1 | METABOLIC BIOMARKERS OF CROHN'S DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-19 | — | — | US | disclosed |
| US-9364424-B2 | Topical cosmetic skin lightening compositions and methods of use thereof | STIEFEL LABORATORIES, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160074315-A1 | TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF | STIEFEL LABORATORIES, INC. | 2016-03-17 | — | — | US | disclosed |
| US-20120238750-A1 | AROMATIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-09-20 | — | — | US | disclosed |
| US-20120213772-A1 | Metabolic biomarkers of Crohn's Disease | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-08-23 | — | — | US | disclosed |
| WO-2011009099-A1 | METABOLIC BIOMARKERS OF CROHN'S DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-1992013823-A1 | AMINOALCOHOLS USEFUL AS OPTICAL RESOLVING AGENTS | LES LABORATOIRES BEECHAM S.A. (FR) | 1992-08-20 | — | — | WO | disclosed |
| US-4439524-A | Stereoselective resolution of phenylglycine derivatives with enzyme resins | BAYER AKTIENGESELLSCHAFT (DE) | 1984-03-27 | — | — | US | disclosed |
| EP-0022492-B1 | STEREO SELECTIVE RESOLUTION OF PHENYLGLYCINE DERIVATIVES WITH ENZYMERESINS | BAYER AG (DE) | 1982-09-29 | — | — | EP | disclosed |
| US-4260684-A | Stereoselective resolution of phenylglycine derivatives and 4-hydroxyphenylglycine derivatives with enzyme resins | BAYER AKTIENGESELLSCHAFT (DE) | 1981-04-07 | — | — | US | disclosed |
| EP-0022492-A1 | Stereo selective resolution of phenylglycine derivatives with enzymeresins | BAYER AG (DE) | 1981-01-21 | — | — | EP | disclosed |
| EP-0003786-B1 | STEREOSELECTIVE SEPARATION OF PHENYLGLYCINE DERIVATIVES AND 4-HYDROXYPHENYLGLYCINE DERIVATIVES WITH ENZYME-CONTAINING POLYMERS | BAYER AG (DE) | 1980-12-10 | — | — | EP | disclosed |
| EP-0003786-A1 | Stereoselective separation of phenylglycine derivatives and 4-hydroxyphenylglycine derivatives with enzyme-containing polymers | BAYER AG (DE) | 1979-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030108496-A1 | Compositions comprising phenyl-glycine derivatives | GRHPR, ARL1, SUCLG1 | MLYCD 1460/4885CA2 1324/4885CAMK2A 4348/4885 |
| US-20120238750-A1 | AROMATIC COMPOUND | CBR1, CBR3, CYP1A1 | MLYCD 2552/4885CA2 2029/4885CAMK2A 4603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.